Newsroom - TRB Chemedica International

Filters

How TRB is proactively addressing the new European Medical Devices Regulation (MDR)

Learn More

TRB Chemedica International S.A. and InnoMedica Holding AG enter in a long-term relationship regarding the production of GM1 (monosialotetrahexosylganglioside) and its development as a liposomal formulation under the trade name Talineuren®

TRB Chemedica announces a collaboration with InnoMedica to develop liposomal GM1

Learn More

Hyaluronic Acid injection and cost TRB Chemedica

Are more expensive products any more clinically effective?

Learn More

european-business-trb-chemedica-interview

Read the European Business magazine interviews of Alessandro di Napoli

Learn More

Presentation of DISSCO results at the WCO-IOF-ESCEO congress in Paris (past event)

Learn More

You are about to leave the TRB corporate website. This link will take you to a local TRB website. Medical practices and regulations can be different from one country to another.

As a result, the medical information provided in the site which you are going to visit may not be appropriate for product use in your country.

CONTINUE